TKTL1在前列腺癌新辅助内分泌治疗前后的表达及临床意义

Expression and Clinical Significance of TKTL1 Before and After the Neoadjuvant Endocrine Therapy for Prostate Cancer

目的研究转酮醇酶样蛋白1(transketolase-like protein 1,TKTL1)在前列腺癌新辅助内分泌治疗前后组织中的表达及临床意义。方法采用免疫组织化学法检测TKTL1在新辅助内分泌治疗前后前列腺癌组织中的表达.并用单因素方差分析法研究其与临床病理因素的关系。结果 TKTL1在新辅助内分泌治疗后的前列腺组织中表达低,差异有统计学意义(P <0.05);TKTL1在前列腺癌中的表达与患者的年龄、肿瘤大小无关(P>0.05),与TNM分期及肿瘤组织分化程度有关(P<0.05)。结论 TKTL1的低表达可以反映新辅助内分泌治疗对前列腺癌的作用,对前列腺癌诊断及判断预后有一定的意义,有可能成为判断前列腺癌预后的一个生物标志物。

Objective To study the expression and clinical significance of TKTL1 in the tissues of prostate cancer before and after the neoadjuvant endocrine therapy. Methods Immunohistochemistry was used to detect the expression of TKTL1 in prostate cancer tissues before and after neoadjuvant endocrine therapy.One-way analysis of variance was used to study its relationship with clinicopathological factors. Results The expression of TKTL1 was significantly lower in prostate tissue after the neoadjuvant endocrine therapy( P <0.05).The expression of TKTL1 in prostate cancer was not related to the patient′s age and tumor size( P >0.05),but related to TNM stage and tumor differentiation( P <0.05). Conclusion The lower expression of TKTL1 can reflect the effect of the neoadjuvant endocrine therapy in prostate cancer.It has certain significance in the diagnosis and prognosis of prostate cancer,and may serve as a biomarker to determine the prognosis of prostate cancer.